Anecortave Acetate Sterile Suspension, 6 mg/mL
DrugSingle injection, anterior juxtascleral depot (AJD)
NCT Number: NCT00320203
The purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of Anecortave Acetate Depot for treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single injection, anterior juxtascleral depot (AJD)
Single injection, anterior juxtascleral depot (AJD)
Single injection, anterior juxtascleral depot (AJD)
Single injection, anterior juxtascleral depot (AJD)
Time frame: Weeks 2 and 6, Months 2, 3, 4, 5, 6, 7.5, 9, 10.5, and 12
Time frame: At time point
Alcon Research
Industry
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05411198
Eye Diseases, Glaucoma
Fayetteville, Arkansas, United States
View Trial DetailsNCT03267134
Eye Diseases, Glaucoma
Fayetteville, Arkansas, United States
View Trial DetailsNCT01699464
Eye Diseases, Glaucoma
View Trial DetailsNCT00856622
Eye Diseases, Glaucoma
Aachen, Germany
View Trial Details